Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–33. https://doi.org/10.1056/nejmoa2001017.
Article
PubMed
PubMed Central
Google Scholar
Guan W, Ni Z, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–20. https://doi.org/10.1056/nejmoa2002032.
Article
CAS
PubMed
Google Scholar
Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033–4. https://doi.org/10.1016/S0140-6736(20)30628-0.
Article
CAS
PubMed
PubMed Central
Google Scholar
Yonas E, Alwi I, Pranata R, et al. Elevated interleukin levels are associated with higher severity and mortality in COVID 19—a systematic review, meta-analysis, and meta-regression. Diabetes Metab Syndr Clin Res Rev. 2020;14(6):2219–30. https://doi.org/10.1016/j.dsx.2020.11.011.
Article
Google Scholar
Li J, Rong L, Cui R, et al. Dynamic changes in serum IL-6, IL-8, and IL-10 predict the outcome of ICU patients with severe COVID-19. Ann Palliat Med. 2021;10(2):62–62. https://doi.org/10.21037/apm-20-2134.
Article
Google Scholar
Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. 2008;371(9617):987–97. https://doi.org/10.1016/S0140-6736(08)60453-5.
Article
CAS
PubMed
Google Scholar
Stone JH, Tuckwell K, Dimonaco S, et al. Trial of tocilizumab in giant-cell arteritis. N Engl J Med. 2017;377(4):317–28. https://doi.org/10.1056/nejmoa1613849.
Article
CAS
PubMed
Google Scholar
Genovese MC, Fleischmann R, Kivitz AJ, et al. Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a phase III study. Arthritis Rheumatol. 2015;67(6):1424–37. https://doi.org/10.1002/art.39093.
Article
CAS
PubMed
Google Scholar
Campochiaro C, Dagna L. The conundrum of interleukin-6 blockade in COVID-19. Lancet Rheumatol. 2020;2(10):e579–80. https://doi.org/10.1016/S2665-9913(20)30287-3.
Article
PubMed
PubMed Central
Google Scholar
Campochiaro C, Della-Torre E, Cavalli G, et al. Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study. Eur J Intern Med. 2020;76:43–9. https://doi.org/10.1016/j.ejim.2020.05.021.
Article
CAS
PubMed
PubMed Central
Google Scholar
Della-Torre E, Campochiaro C, Cavalli G, et al. Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study. Ann Rheum Dis. 2020;79(10):1277–85. https://doi.org/10.1136/annrheumdis-2020-218122.
Article
CAS
PubMed
Google Scholar
Monti G, Campochiaro C, Zangrillo A, et al. Immunosuppressive strategies in invasively ventilated ARDS COVID-19 patients. Minerva Anestesiol. 2021;87(8):891–902. https://doi.org/10.23736/S0375-9393.21.15339-8.
Article
PubMed
Google Scholar
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339(7716):332–6. https://doi.org/10.1136/bmj.b2535.
Article
Google Scholar
Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009;151(4):W65–94. https://doi.org/10.7326/0003-4819-151-4-200908180-00136.
Article
PubMed
Google Scholar
Greco T, Zangrillo A, Biondi-Zoccai G, Landoni G. Meta-analysis: pitfalls and hints. Hear Lung Vessel. 2013;5(4):219–25.
CAS
Google Scholar
Biondi-Zoccai G, Lotrionte M, Landoni G, Modena MG. The rough guide to systematic reviews and meta-analyses. HSR Proc Intensive Care Cardiovasc Anesth. 2011;3(3):161–73.
CAS
PubMed
PubMed Central
Google Scholar
Higgins J, Thomas J, Chandler J, et al., eds. Cochrane Handbook for Systematic Reviews of Interventions. 2nd ed. Chichester (UK): John Wiley & Sons; 2019. https://training.cochrane.org/cochrane-handbook-systematic-reviews-interventions. Accessed 7 Jan 2021.
Domingo P, Mur I, Mateo GM, et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19. JAMA. 2021;326(6):499–518. https://doi.org/10.1001/jama.2021.11330.
Article
CAS
PubMed
Google Scholar
Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14(1):135. https://doi.org/10.1186/1471-2288-14-135.
Article
PubMed
PubMed Central
Google Scholar
Sterne JAC, Sutton AJ, Ioannidis JPA, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ. 2011;343(7818): d4002. https://doi.org/10.1136/bmj.d4002.
Article
PubMed
Google Scholar
Sterne JAC, Savović J, Page MJ, et al. RoB 2: A revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366: l4898. https://doi.org/10.1136/bmj.l4898.
Article
PubMed
Google Scholar
Ravinetto R, Caillet C, Zaman MH, et al. Preprints in times of COVID19: the time is ripe for agreeing on terminology and good practices. BMC Med Ethics. 2021;22(1):106. https://doi.org/10.1186/s12910-021-00667-7.
Article
PubMed
PubMed Central
Google Scholar
Landoni G, Pieri M, Young PJ, Bellomo R. Why do multicenter randomized controlled trials not confirm the positive findings of single center randomized controlled trials in acute care? Minerva Anestesiol. 2019;85(2):194–200. https://doi.org/10.23736/S0375-9393.18.13070-7.
Article
PubMed
Google Scholar
Bellomo R, Warrillow SJ, Reade MC. Why we should be wary of single-center trials. Crit Care Med. 2009;37(12):3114–9. https://doi.org/10.1097/CCM.0b013e3181bc7bd5.
Article
PubMed
Google Scholar
Baiardo Redaelli M, Belletti A, Monti G, et al. The impact of non-blinding in critical care medicine trials. J Crit Care. 2018;48:414–7. https://doi.org/10.1016/j.jcrc.2018.09.031.
Article
CAS
PubMed
Google Scholar
Brok J, Thorlund K, Gluud C, Wetterslev J. Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses. J Clin Epidemiol. 2008;61(8):763–9. https://doi.org/10.1016/j.jclinepi.2007.10.007.
Article
PubMed
Google Scholar
Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. J Clin Epidemiol. 2008;61(1):64–75. https://doi.org/10.1016/j.jclinepi.2007.03.013.
Article
PubMed
Google Scholar
Somers EC, Eschenauer GA, Troost JP, et al. Tocilizumab for treatment of mechanically ventilated patients with COVID-19. medRxiv. 2020. https://doi.org/10.1101/2020.05.29.20117358.
Article
PubMed
PubMed Central
Google Scholar
Gupta S, Wang W, Hayek SS, et al. Association between early treatment with tocilizumab and mortality among critically Ill patients with COVID-19. JAMA Intern Med. 2021;181(1):41–51. https://doi.org/10.1001/jamainternmed.2020.6252.
Article
CAS
PubMed
Google Scholar
Strohbehn GW, Heiss BL, Rouhani SJ, et al. COVIDOSE: Low-dose tocilizumab in the treatment of Covid-19. medRxiv. 2020. https://doi.org/10.1101/2020.07.20.20157503.
Article
PubMed
PubMed Central
Google Scholar
Garcia-Vicuña R, Abad-Santos F, González-Alvaro I, Ramos-Lima F, Sanz JS. Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial. Trials. 2020;21(1):772. https://doi.org/10.1186/s13063-020-04588-5.
Article
CAS
PubMed
PubMed Central
Google Scholar
León López R, Fernández SC, Limia Pérez L, et al. Efficacy and safety of early treatment with sarilumab in hospitalised adults with COVID-19 presenting cytokine release syndrome (SARICOR STUDY): protocol of a phase II, open-label, randomised, multicentre, controlled clinical trial. BMJ Open. 2020;10(11): e039951. https://doi.org/10.1136/bmjopen-2020-039951.
Article
PubMed
PubMed Central
Google Scholar
Maes B, Bosteels C, De Leeuw E, et al. Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): a structured summary of a study protocol for a randomised controlled trial. Trials. 2020;21(1):468. https://doi.org/10.1186/s13063-020-04453-5.
Article
CAS
PubMed
PubMed Central
Google Scholar
Rashad A, Mousa S, Nafady-Hego H, Nafady A, Elgendy H. Short term survival of critically ill COVID-19 Egyptian patients on assisted ventilation treated by either dexamethasone or tocilizumab. Sci Rep. 2021;11(1):8816. https://doi.org/10.1038/s41598-021-88086-x.
Article
CAS
PubMed
PubMed Central
Google Scholar
Salvarani C, Dolci G, Massari M, et al. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: a randomized clinical trial. JAMA Intern Med. 2021;181(1):24–31. https://doi.org/10.1001/jamainternmed.2020.6615.
Article
CAS
PubMed
Google Scholar
Stone JH, Frigault MJ, Serling-Boyd NJ, et al. Efficacy of tocilizumab in patients hospitalized with Covid-19. N Engl J Med. 2020;383(24):2333–44. https://doi.org/10.1056/nejmoa2028836.
Article
CAS
PubMed
Google Scholar
Hermine O, Mariette X, Tharaux PL, Resche-Rigon M, porcher R, ravaud p. effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial. JAMA Intern Med. 2021;181(1):32–40. https://doi.org/10.1001/jamainternmed.2020.6820.
Article
CAS
PubMed
Google Scholar
Salama C, Han J, Yau L, et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. N Engl J Med. 2020;384(1):20–30. https://doi.org/10.1056/nejmoa2030340.
Article
CAS
PubMed
Google Scholar
Zhao H, Zhu Q, Zhang C, et al. Tocilizumab combined with favipiravir in the treatment of COVID-19: a multicenter trial in a small sample size. Biomed Pharmacother. 2021;133: 110825. https://doi.org/10.1016/j.biopha.2020.110825.
Article
CAS
PubMed
Google Scholar
Rosas IO, Bräu N, Waters M, et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. N Engl J Med. 2021;384(16):1503–26. https://doi.org/10.1056/NEJMoa2028700.
Article
CAS
PubMed
Google Scholar
Veiga VC, Prats JAGG, Farias DLC, et al. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ. 2021;372: n84. https://doi.org/10.1136/bmj.n84.
Article
PubMed
Google Scholar
Wang D, Fu B, Peng Z, et al. Tocilizumab ameliorates the hypoxia in COVID-19 moderate patients with bilateral pulmonary lesions: a randomized, controlled, open-label, Multicenter Trial. SSRN Electron J. 2020. https://doi.org/10.2139/ssrn.3667681.
Article
Google Scholar
RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397(10285):1637–45. https://doi.org/10.1016/S0140-6736(21)00676-0.
Article
Google Scholar
Talaschian M, Akhtari M, Mahmoudi M, et al. Tocilizumab failed to reduce mortality in severe COVID-19 patients: results from a randomized controlled clinical trial. Res Sq. 2021. https://doi.org/10.21203/RS.3.RS-463921/V1.
Article
Google Scholar
Lescure F-X, Honda H, Fowler RA, et al. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021;9(5):522–32. https://doi.org/10.1016/S2213-2600(21)00099-0.
Article
CAS
PubMed
PubMed Central
Google Scholar
Soin AS, Kumar K, Choudhary NS, et al. Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial. Lancet Respir Med. 2021;9(5):511–21. https://doi.org/10.1016/S2213-2600(21)00081-3.
Article
CAS
PubMed
PubMed Central
Google Scholar
Sivapalasingam S, Lederer DJ, Bhore R, et al. A randomized placebo-controlled trial of sarilumab in hospitalized patients with Covid-19. MedRxiv. 2021. https://doi.org/10.1101/2021.05.13.21256973.
Article
Google Scholar
Gordon AC, Mouncey PR, Al-Beidh F, et al. Interleukin-6 receptor antagonists in critically Ill patients with Covid-19. N Engl J Med. 2021;384(16):1491–502. https://doi.org/10.1056/NEJMoa2100433.
Article
PubMed
Google Scholar
Rutgers A, Westerweel PE, van der Holt B, et al. Timely administration of tocilizumab improves survival of hospitalized COVID-19 patients. SSRN Electron J. 2021. https://doi.org/10.2139/SSRN.3834311.
Article
Google Scholar
Hariyanto TI, Hardyson W, Kurniawan A. Efficacy and safety of tocilizumab for coronavirus disease 2019 (Covid-19) patients: a systematic review and meta-analysis. Drug Res. 2021;71(5):265–74. https://doi.org/10.1055/a-1336-2371.
Article
CAS
Google Scholar
Tleyjeh IM, Kashour Z, Damlaj M, et al. Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis. Clin Microbiol Infect. 2021;27(2):215–27. https://doi.org/10.1016/j.cmi.2020.10.036.
Article
CAS
PubMed
Google Scholar
Khan FA, Stewart I, Fabbri L, et al. Systematic review and meta-analysis of anakinra, sarilumab, siltuximab and tocilizumab for COVID-19. Thorax. 2021;76(9):907–19. https://doi.org/10.1136/thoraxjnl-2020-215266.
Article
PubMed
Google Scholar
Berardicurti O, Ruscitti P, Ursini F, et al. Mortality in tocilizumab-treated patients with COVID-19: a systematic review and meta-analysis. Clin Exp Rheumatol. 2020;38(6):1247–54.
PubMed
Google Scholar
Kim MS, An MH, Kim WJ, Hwang TH. Comparative efficacy and safety of pharmacological interventions for the treatment of COVID-19: a systematic review and network meta-analysis. PLoS Med. 2020;17(12): e1003501. https://doi.org/10.1371/journal.pmed.1003501.
Article
CAS
PubMed
PubMed Central
Google Scholar
Sarfraz A, Sarfraz Z, Sarfraz M, Aftab H, Pervaiz Z. Tocilizumab and COVID-19: a meta-analysis of 2120 patients with severe disease and implications for clinical trial methodologies. Turkish J Med Sci. 2021;51(3):890–7. https://doi.org/10.3906/sag-2010-131.
Article
CAS
Google Scholar
Aziz M, Haghbin H, Abu Sitta E, et al. Efficacy of tocilizumab in COVID-19: a systematic review and meta-analysis. J Med Virol. 2021;93(3):1620–30. https://doi.org/10.1002/jmv.26509.
Article
CAS
PubMed
Google Scholar
Malgie J, Schoones JW, Pijls BG. Decreased mortality in Coronavirus Disease 2019 patients treated with tocilizumab: a rapid systematic review and meta-analysis of observational studies. Clin Infect Dis. 2021;72(11):e742–9. https://doi.org/10.1093/cid/ciaa1445.
Article
CAS
PubMed
Google Scholar
Kotak S, Khatri M, Malik M, et al. Use of tocilizumab in COVID-19: a systematic review and meta-analysis of current evidence. Cureus. 2020;12(10): e10869. https://doi.org/10.7759/cureus.10869.
Article
PubMed
PubMed Central
Google Scholar
Kow CS, Hasan SS. The effect of tocilizumab on mortality in hospitalized patients with COVID-19: a meta-analysis of randomized controlled trials. Eur J Clin Pharmacol. 2021;77(8):1089–94. https://doi.org/10.1007/s00228-021-03087-z.
Article
CAS
PubMed
Google Scholar
Snow TAC, Saleem N, Ambler G, Nastouli E, Singer M, Arulkumaran N. Tocilizumab in COVID-19: a meta-analysis, trial sequential analysis, and meta-regression of randomized-controlled trials. Intensive Care Med. 2021;47(6):641–52. https://doi.org/10.1007/s00134-021-06416-z.
Article
CAS
PubMed
PubMed Central
Google Scholar
Giacobbe DR, Battaglini D, Ball L, et al. Bloodstream infections in critically ill patients with COVID-19. Eur J Clin Invest. 2020;50(10): e13319. https://doi.org/10.1111/eci.13319.
Article
CAS
PubMed
Google Scholar
Buetti N, Ruckly S, de Montmollin E, et al. COVID-19 increased the risk of ICU-acquired bloodstream infections: a case–cohort study from the multicentric OUTCOMEREA network. Intensive Care Med. 2021;47(2):180–7. https://doi.org/10.1007/s00134-021-06346-w.
Article
CAS
PubMed
PubMed Central
Google Scholar
Ripa M, Galli L, Poli A, et al. Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors. Clin Microbiol Infect. 2021;27(3):451–7. https://doi.org/10.1016/j.cmi.2020.10.021.
Article
CAS
PubMed
Google Scholar
Zangrillo A, Beretta L, Silvani P, et al. Fast reshaping of intensive care unit facilities in a large metropolitan hospital in Milan, Italy: facing the COVID-19 pandemic emergency. Crit Care Resusc. 2020;22(2):91–4.
PubMed
Google Scholar
Monti G, Cremona G, Zangrillo A, et al. Home ventilators for invasive ventilation of patients with COVID-19. Crit Care Resusc. 2020;22(3):266–70.
PubMed
Google Scholar
Biondi-Zoccai GGL, Agostoni P, Abbate A. Parallel hierarchy of scientific studies in cardiovascular medicine. Ital Hear J. 2003;4(11):819–20.
Google Scholar
Biondi-Zoccai G, Landoni G, Modena MG. A journey into clinical evidence: from case reports to mixed treatment comparisons. HSR Proc Intensive Care Cardiovasc Anesth. 2011;3(2):93–6.
CAS
PubMed
PubMed Central
Google Scholar